Mangoceuticals Sues Former Tech Partner Over Platform Dispute

Mangoceuticals, Inc. ( (MGRX) ) has issued an announcement.

On March 16, 2026, Mangoceuticals’ board, acting on recommendations from its compensation and audit committees, approved a repricing of Chief Executive Officer and Chairman Jacob Cohen’s stock options, reducing their exercise prices to $0.45 per share, slightly above the company’s closing share price that day. Cohen recused himself from the vote, and the move aligns his equity incentives more closely with the current market value after earlier grants at exercise prices ranging from $2.30 to $16.50 had fallen out of the money.

On March 17, 2026, the company filed a civil lawsuit in Texas state court against its former technology consulting and software development firm, Clarity Ventures, Inc., seeking more than $73 million in damages over an allegedly undelivered HIPAA-compliant ERP and e-commerce platform. Clarity has denied the allegations and lodged counterclaims over unpaid invoices, while Mangoceuticals says it has fully paid required amounts, has since built its own proprietary telehealth and e-commerce platform, and reports that this internally developed system is improving customer acquisition, order fulfillment, and operating performance.

More about Mangoceuticals, Inc.

Mangoceuticals, Inc., which operates under the brands MangoRx and PeachesRx, is a telemedicine-focused health and wellness company specializing in men’s products such as erectile dysfunction treatments, hair growth therapies, hormone replacement, and weight management drugs. The company sells prescription-based pharmaceutical products via a secure online platform, with licensed medical providers reviewing requests and partner pharmacies discreetly fulfilling and shipping orders to consumers’ homes.

Average Trading Volume: 7,595,330

Technical Sentiment Signal: Sell

Current Market Cap: $6.58M

For detailed information about MGRX stock, go to TipRanks’ Stock Analysis page.